Inogatran

Cat. No.: HY-19660
CAS No.: 155415-08-0
Molecular Formula: $C_{21}H_{38}N_6O_4$
Molecular Weight: 438.56
Target: Thrombin
Pathway: Metabolic Enzyme/Protease
Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

**BIOLICAL ACTIVITY**

<table>
<thead>
<tr>
<th>Description</th>
<th>Inogatran (H-314-27) is a synthetic thrombin inhibitor, developed for the possible treatment and prophylaxis of arterial and venous thrombotic diseases.</th>
</tr>
</thead>
<tbody>
<tr>
<td>In Vivo</td>
<td>Inogatran (H-314-27; 0.075, 0.25, 0.75 mg/kg, i.v.) results in dose-dependent increases in activated partial thromboplastin time (aPTT), thrombin time (TT), and prothrombin time (PT) in a canine electrolytic injury model of venous thrombosis. Inogatran dose-dependently inhibits thrombus formation, which is measured as an increase in time to occlusion (TTO) and a decrease in thrombus weight. Inogatran also improves vena caval blood flow and reduces the overall incidence of thrombotic occlusion in a rat model. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</td>
</tr>
</tbody>
</table>

**REFERENCES**


---

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898  Fax: 609-228-5909  E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA